Safety, tolerability, and preliminary anti-tumor activity of the CX3CR1 antagonist KAND567 in combination with carboplatin in recurrent epithelial ovarian cancer: results from the phase 1b/2a KANDOVA trial

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Hanna Mellin Dahlstrand, Magnus Frödin-Bolling, Anthoula Koliadi, Johan Bring, Susanne Malander, Trine Lembrecht Jørgensen, Johanne Hestvang, Johan Schultz, Mari Bunkholt Elstrand, Jeffrey Yachnin, Robert Edfors, Olesya Solheim
+8 more Emelie Wallin, Maria Bonnée, Katharina Bischof, Elisabeth Åvall Lundqvist, Josefin Fernebro, Camilla Sköld, Kristine Madsen, Kristina Yvonne Lindemann
DOI: 10.1016/j.ijgc.2025.103750
Cited by: 0

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Endometrial and Cervical Cancer Treatments

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103750–103750
Publication date
1 February 2026
Language
EN